Published in Physician Law Weekly, March 23rd, 2005
The alliance provides Ionix with development and commercialization capabilities for its lead product candidate, IX-1003 for the treatment of post-operative pain.
In addition, Ionix and Reckitt Benckiser intend to collaborate on the development and commercialization of two new product candidates, IX-1004 for the treatment of chronic pain and IX-1005 for the treatment of opiate addiction.
As part of the alliance, Ionix will manage a phase II clinical trial of IX-1003...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly